Introduction: The presence of tumor cells in pelvic cytology (PC) specimens can portend a worse outcome for patients undergoing gynecologic surgery. Primary debulking surgery (PDS) was a mainstay for most of these tumors; however, recent advances have triaged selected patients to neoadjuvant chemotherapy (NACT) with interval debulking surgery (IDS). Reduction in tumor cellularity and histologic alterations has been noted in these cases; however, similar cytologic characterization has not been performed. Materials and Methods: PC was searched to find those in NACT patients. Additional PDS were included as controls. Cases were scored for cellularity of malignant cells and background components were described, and when available, pretreatment and posttreatment specimens from the same patients were compared. Results: In all, 19 specimens from 16 patients were found, 6 (32%) of which were paired PTS and IDS from the same patient. Only 6/19 (32%) were from IDS, the remainder PTS. A majority (15/19; 79%) of specimens were malignant; all negative cases were PTS. Few (4/16; 24%) were endometrial primaries; the remainder were pelvic high-grade serous carcinoma. No difference in tumor cell morphology or inflammatory component was noted between the 2 groups, though in 3/3 paired specimens from PDS and IDS, the cellularity of malignant cells decreased in the IDS specimens. Discussion/Conclusion: No identifiable trend was noted regarding cellularity of specimens in the pre compared to the post-neoadjuvant setting. A trend toward reduced cellularity was noted in individual patients, but no alteration in background cells or tumor morphology was noted.

1.
Davidson
W
,
Madan
R
,
O'Neil
M
,
Tawfik
OW
,
Fan
F
.
Utility of peritoneal washing cytology in staging and prognosis of ovarian and fallopian tube neoplasms: a 10-year retrospective analysis
.
Ann Diagn Pathol
.
2016
;
22
:
54
7
.
2.
Berek
JS
,
Renz
M
,
Kehoe
S
,
Kumar
L
,
Friedlander
M
.
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
.
Int J Gynaecol Obstet
.
2021
;
155
(
Suppl 1
):
61
85
. .
3.
Suh
DH
,
Kim
TH
,
Kim
JW
,
Kim
SY
,
Kim
HS
,
Lee
TS
,
Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture
.
J Gynecol Oncol
.
2013
;
24
:
352
8
.
4.
Garg
G
,
Gao
F
,
Wright
JD
,
Hagemann
AR
,
Mutch
DG
,
Powell
MA
.
Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer
.
Gynecol Oncol
.
2013
;
128
:
77
82
.
5.
Kasamatsu
T
,
Onda
T
,
Katsumata
N
,
Sawada
M
,
Yamada
T
,
Tsunematsu
R
,
Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus
.
Br J Cancer
.
2003
;
88
:
245
50
.
6.
National Comprehensive Cancer Network
.
Uterine Cancer (Version 2.2002)
. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf Accessed 2021 Mar 23.
7.
National Comprehensive Cancer Network
.
Ovarian Cancer (Version 2.2002)
. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf Accessed 2021 Mar 23.
8.
Vergote
I
,
Tropé
CG
,
Amant
F
,
Kristensen
GB
,
Ehlen
T
,
Johnson
N
,
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
.
N Engl J Med
.
2010
;
363
:
943
53
.
9.
Kehoe
S
,
Hook
J
,
Nankivell
M
,
Jayson
GC
,
Kitchener
H
,
Lopes
T
,
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
.
Lancet
.
2015
;
386
:
249
57
.
10.
Böhm
S
,
Faruqi
A
,
Said
I
,
Lockley
M
,
Brockbank
E
,
Jeyarajah
A
,
Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma
.
J Clin Oncol
.
2015
;
33
:
2457
63
.
11.
Singh
P
,
Kaushal
V
,
Rai
B
,
Rajwanshi
A
,
Gupta
N
,
Dey
P
,
The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma
.
Histopathology
.
2018
;
72
:
619
25
.
12.
Cohen
PA
,
Powell
A
,
Böhm
S
,
Gilks
CB
,
Stewart
CJR
,
Meniawy
TM
,
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data
.
Gynecol Oncol
.
2019
;
154
:
441
8
.
13.
Iura
A
,
Takita
M
,
Kawano
A
,
Imai
K
,
Konnai
K
,
Onose
R
,
Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
.
J Gynecol Oncol
.
2018
;
29
:
e70
.
14.
Mount
SL
,
Horton
M
.
Changes in staging and advances in treatment for gynecological malignancies: the impact on cytopathology
.
Cancer Cytopathol
.
2014
;
122
:
317
21
. .
15.
Bansal
A
,
Srinivasan
R
,
Rohilla
M
,
Sundaram
A
,
Rai
B
,
Rajwanshi
A
,
Morphologic and immunocytochemical features of high-grade serous carcinoma of ovary in ascitic fluid effusion and fine-needle aspiration cytology
.
Am J Clin Pathol
.
2020
;
154
:
103
14
.
16.
Gupta
N
,
Soni
A
,
Mahajan
R
,
Selhi
P
,
Tyagi
R
,
Garg
B
,
Peritoneal malignant mesothelioma: slippery like an eel to diagnose on cytology-case series of 3 cases
.
J Am Soc Cytopathol
.
2022 Jan-Feb
;
11
(
1
):
40
5
. .
17.
Taylor
J
,
Shah
R
,
McElvanna
K
,
Kelly
PJ
,
McCluggage
WG
.
Late development of metastatic ovarian mucinous adenocarcinoma from primary gallblader adenocarcinoma and high-grade dysplasia
.
Int J Gynecol Pathol
.
2021
;
40
:
41
8
. .
18.
Khandakar
B
,
Kumar
L
,
Kumar
S
,
Gupta
SD
,
Kalaivani
M
,
Iyer
V
,
Tumour morphology after neoadjuvant chemotherapy as a predictor of survival in serous ovarian cancer: an experience from a tertiary care centre in India
.
Malays J Pathol
.
2015
;
37
:
115
21
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.